DE60319135D1 - Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden - Google Patents

Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden

Info

Publication number
DE60319135D1
DE60319135D1 DE60319135T DE60319135T DE60319135D1 DE 60319135 D1 DE60319135 D1 DE 60319135D1 DE 60319135 T DE60319135 T DE 60319135T DE 60319135 T DE60319135 T DE 60319135T DE 60319135 D1 DE60319135 D1 DE 60319135D1
Authority
DE
Germany
Prior art keywords
vegfr
vegf
binding domain
binding
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319135T
Other languages
German (de)
English (en)
Inventor
Mari Ann Kulseth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Application granted granted Critical
Publication of DE60319135D1 publication Critical patent/DE60319135D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
DE60319135T 2002-12-30 2003-12-29 Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden Expired - Lifetime DE60319135D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20026286A NO20026286D0 (no) 2002-12-30 2002-12-30 Nye peptider
PCT/NO2003/000444 WO2004058802A1 (en) 2002-12-30 2003-12-29 Peptides that bind to the heparin binding domian of vegf and vegfr-2

Publications (1)

Publication Number Publication Date
DE60319135D1 true DE60319135D1 (de) 2008-03-27

Family

ID=19914347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319135T Expired - Lifetime DE60319135D1 (de) 2002-12-30 2003-12-29 Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden

Country Status (8)

Country Link
US (1) US20060089307A1 (https=)
EP (1) EP1578785B1 (https=)
JP (1) JP2006523608A (https=)
AT (1) ATE386050T1 (https=)
AU (1) AU2003288810A1 (https=)
DE (1) DE60319135D1 (https=)
NO (1) NO20026286D0 (https=)
WO (1) WO2004058802A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
CA2583399A1 (en) * 2004-10-14 2006-04-27 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
CN101272808B (zh) 2005-01-06 2012-03-21 通用电气医疗集团股份有限公司 光学成像
JP6758022B2 (ja) * 2012-09-03 2020-09-23 国立大学法人 東京大学 血管内皮細胞増殖因子受容体阻害ペプチド
KR101531944B1 (ko) * 2013-12-24 2015-06-29 광주과학기술원 Ｖｅｇｆ에 특이적으로 결합하는 ｖｅｇｆ－ｂｐｂ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5948667A (en) * 1996-11-13 1999-09-07 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Xylanase obtained from an anaerobic fungus
WO1999010498A2 (en) * 1997-08-27 1999-03-04 Pioneer Hi-Bred International, Inc. Genes encoding enzymes for lignin biosynthesis and uses thereof
WO1999014321A1 (en) * 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
AU757554B2 (en) * 1998-02-11 2003-02-27 Bracco International B.V. Angiogenesis targeting molecules
EP1248642A4 (en) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
MXPA04000564A (es) * 2001-07-20 2005-02-17 Univ Zuerich Composiciones y metodos para uso de agentes bioactivos derivados de aminoacidos sulfatados y sulfonados.
CA2666005C (en) * 2002-03-01 2016-01-19 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy

Also Published As

Publication number Publication date
AU2003288810A1 (en) 2004-07-22
US20060089307A1 (en) 2006-04-27
ATE386050T1 (de) 2008-03-15
EP1578785B1 (en) 2008-02-13
EP1578785A1 (en) 2005-09-28
NO20026286D0 (no) 2002-12-30
WO2004058802A1 (en) 2004-07-15
JP2006523608A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
DE60028970D1 (de) An her2 bindende peptidverbindungen
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EP1764370A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
EA201100694A1 (ru) Антитело к cd38 человека и его применение
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
PT1187918E (pt) Antagonistas de tek
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ATE386050T1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
WO2004058803A3 (en) Peptides that bind of the vegfr-2
EA200501846A1 (ru) Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
ATE402958T1 (de) Antagonisten des ige-rezeptors
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE480552T1 (de) Stq-peptide
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
WO2023166318A3 (en) Therapeutic antibodies
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE412903T1 (de) Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Legal Events

Date Code Title Description
8332 No legal effect for de